Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.
Overview of Charles River Laboratories International, Inc. (CRL)
Charles River Laboratories International, Inc. (CRL) is a globally recognized contract research organization (CRO) that provides essential services to pharmaceutical, biotechnology, academic, and government clients. The company specializes in supporting the discovery, development, and safe manufacturing of new therapies, playing a pivotal role in the life sciences ecosystem. With a comprehensive portfolio of products and services, CRL helps its clients accelerate research timelines and optimize the drug development process, making it a critical partner in the creation of innovative treatments for patients worldwide.
Core Business Areas
Charles River Laboratories operates across several key business segments, each tailored to meet the diverse needs of its clients:
- Discovery and Early-Stage Development: CRL provides services that span the early phases of drug discovery, including target identification, validation, and preclinical testing. These services are designed to help clients identify viable drug candidates efficiently.
- Safety Assessment: The company offers toxicology and safety evaluation services to ensure that new therapies meet regulatory requirements and are safe for further development.
- Research Models and Services: CRL supplies high-quality research models, including genetically engineered models, as well as associated services to support in vivo research.
- Manufacturing Support: The company provides services such as microbial detection, biopharmaceutical testing, and cell and gene therapy manufacturing support, which are critical for ensuring the quality and safety of therapeutic products.
Market Position and Industry Context
Operating at the intersection of biotechnology, pharmaceuticals, and academic research, Charles River Laboratories serves a growing market driven by the increasing complexity and cost of drug development. The rise of precision medicine, biologics, and cell and gene therapies has further expanded the demand for specialized CRO services. CRL differentiates itself through its end-to-end service offerings, global infrastructure, and expertise in early-stage research, making it a preferred partner for organizations looking to outsource R&D activities. Its ability to integrate discovery, safety assessment, and manufacturing support under one roof provides a seamless experience for clients, reducing time-to-market for new therapies.
Competitive Landscape
Charles River Laboratories faces competition from other CROs such as Labcorp Drug Development, ICON plc, and PPD. However, its focus on early-stage research, coupled with a broad service portfolio and a strong reputation for scientific expertise, sets it apart. The company's investments in technology, innovation, and global infrastructure further strengthen its competitive position, enabling it to address the evolving needs of the life sciences industry.
Significance in the Life Sciences Ecosystem
As a trusted partner to pharmaceutical and biotechnology companies, Charles River Laboratories plays a crucial role in advancing medical innovation. By providing specialized expertise and resources, the company helps its clients navigate the complexities of drug development, ensuring that new therapies reach patients more efficiently. This makes CRL an indispensable player in the global effort to improve healthcare outcomes.
Charles River Laboratories (NYSE: CRL) has entered an agreement with Singapore General Hospital (SGH) to provide CGMP-compliant master cell banking and next-generation sequencing (NGS) services. These services will aid in the characterization of cell lines derived from cord blood for allogeneic CAR-T cell production, aimed at treating cancer patients.
SGH will utilize Charles River's CGMP master cell banking services and NGS-based testing for their upcoming Phase I clinical trials. The NGS technology offers high throughput, scalability, and speed, revolutionizing genetic analysis and pathogen detection. It provides a more efficient and reliable testing option compared to traditional animal-based testing.
Charles River's services ensure compliance with GMP, FDA, EMA, and ICH Q5A and Q5B standards, accelerating development timelines without compromising safety. The company offers a full range of CGMP-compliant cell bank production and storage services, including 9 ISO-6 cleanroom suites and a cell bank completion to release timeline of 8-10 weeks.
Charles River Laboratories reported Q4 2024 revenue of $1.00 billion, down 1.1% from Q4 2023, and full-year 2024 revenue of $4.05 billion, a 1.9% decrease from 2023. The company posted a Q4 GAAP loss per share of $(4.22), primarily due to a $215.0 million non-cash goodwill impairment related to the Biologics Solutions unit.
Full-year 2024 GAAP earnings were $0.20 per share, while non-GAAP earnings reached $10.32 per share. The company's organic revenue declined by 2.8% in 2024. For 2025, Charles River projects an organic revenue decrease of 3.5% to 5.5% and non-GAAP EPS of $9.10 to $9.60.
The company announced plans for $350 million in stock repurchases for 2025. Management noted continued constraints in early-stage spending by global biopharmaceutical clients, while expecting stable to slightly improved demand from small and mid-sized biotechnology clients.
Charles River Laboratories (NYSE: CRL) and Deciphex have announced an expansion of their strategic partnership to advance digital pathology solutions. The collaboration focuses on integrating the Patholytix platform across Charles River's global network to enhance image management, distribution, and archiving workflows in toxicologic pathology.
Building on their successful 2024 launch of Foresight, the partnership aims to develop advanced AI tools for toxicologic pathology, including new screening capabilities for acute toxicity and carcinogenicity studies. The integrated system is expected to streamline digital workflows, reduce turnaround times, and enable better collaboration across global teams.
The partnership combines Deciphex's digital pathology expertise with Charles River's toxicologic pathology network, offering clients enhanced capabilities for primary evaluation and peer review in toxicologic pathology assessment, ultimately accelerating drug development and safety assessment processes.
Charles River Laboratories (NYSE: CRL) has announced it will release its fourth-quarter and full-year 2024 financial results along with 2025 guidance on Wednesday, February 19th, before market opening. The company has scheduled a conference call at 8:30 a.m. ET on the same day to discuss these results.
Investors can access a live webcast of the conference call through the Investor Relations section of the company's website at ir.criver.com. A replay of the call will also be made available through the same platform.
Charles River Laboratories (NYSE: CRL) announced the launch of Apollo™ for CRADL®, a secure cloud-based platform enhancing their vivarium rental services. The platform streamlines research initiation by providing a centralized dashboard connecting clients to online training, research models ordering, and study support services.
Apollo serves as the technology stack driving Charles River's digital transformation, offering expanded client access across their portfolio through multiple integrations:
- Apollo for CRADL: Streamlines administrative tasks for vivarium rental solutions
- Apollo for Safety Assessment: Provides real-time access to data visualization and program planning
- Apollo for Biologics: Centralizes sample submission and tracking
- Apollo for Discovery: Enables instant oncology study price estimates
- Apollo for Logica®: Delivers real-time updates for AI-powered small molecule programs
- Research Models Online Ordering System: Offers interactive catalog with real-time inventory
Charles River Laboratories (NYSE: CRL) and Akron Bio announced the integration of Akron's Closed System Solutions (CSS)™ line of liquid cytokines into Charles River's Cell Therapy Flex Platform for Process Development. This integration aims to enhance closed system processing, streamline operations, and improve process robustness.
The Cell Therapy Flex Platform, designed as an off-the-shelf solution for Cell Therapy Process Development, now incorporates Akron's CGMP liquid cytokines, including rHu IL-2, IL-7, IL-15, and IL-21. These cytokines are available in single-use bags with weldable tubing, maintaining stability at 2-8°C and enabling rapid, aseptic media formulation while minimizing operator error.
This collaboration enhances manufacturing efficiency by decreasing labor requirements and improving process robustness for CAR-T and TCR-T cell therapies development.
Charles River Laboratories (NYSE: CRL) has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 2:15 p.m. PT (5:15 p.m. ET). The presentation will feature management's overview of the company's strategic focus, business developments, and recent trends.
Investors and interested parties can access a live webcast of the presentation through a link that will be available on the Investor Relations section of Charles River's website at ir.criver.com. A replay of the webcast will be accessible through the same website following the presentation and will remain available for a minimum of two weeks.
Deciphex has secured $32.3 million in Series C funding led by Molten Ventures, with participation from multiple investors including Charles River Laboratories (NYSE: CRL). The funding aims to address the global pathology shortage, where over 70% of healthcare decisions require pathology investigation amid declining pathologist numbers.
The company's AI-powered platforms, Diagnexia and Patholytix, enable pathologists to work up to 40% faster while maintaining diagnostic accuracy. The funding will support global expansion across the US, UK, EU, Canada, and Japan, enhance platform capabilities, accelerate AI foundational model development, strengthen partnerships with industry leaders like Novartis and Charles River Laboratories, and expand services to pharmaceutical, biotech, and CRO clients.
Charles River Laboratories (NYSE: CRL) has launched the Charles River Incubator Program (CIP), aimed at supporting early-stage biotechnology companies in the discovery, development, and manufacturing of advanced therapies. Through its Global Innovation Center of Excellence, CIP offers knowledge, connectivity, and priority access to Charles River's extensive portfolio. This initiative builds on the success of the Cell and Gene Therapy Accelerator Program (CAP), designed to assist companies 18-24 months from Investigational New Drug (IND) or Clinical Trial Application (CTA) submission. CIP targets companies 24+ months from IND or CTA submission, providing regulatory and quality expertise, personnel training, and access to laboratory space and equipment. The Global Innovation Center of Excellence integrates a team of scientific, regulatory, and manufacturing experts to foster innovation and support thousands of IND and CTA submissions. The next cohort will be shortlisted at the Cell and Gene Therapy Summit on March 4, 2025, in San Francisco, CA.
Charles River Laboratories (NYSE: CRL) announced its participation in the 7th Annual Evercore ISI HealthCONx Conference on Wednesday, December 4th, at 10:00 a.m. ET. During the event, the management will discuss strategic focus, business developments, and recent trends. A live webcast of the presentation will be accessible via the Investor Relations section of the Charles River website at ir.criver.com. The webcast replay will be available on the same site for at least two weeks post-presentation.
FAQ
What is the current stock price of Charles Riv Labs Intl (CRL)?
What is the market cap of Charles Riv Labs Intl (CRL)?
What does Charles River Laboratories International, Inc. do?
What industries does Charles River Laboratories serve?
How does Charles River Laboratories generate revenue?
What sets Charles River Laboratories apart from competitors?
What role does Charles River Laboratories play in drug development?
Who are the competitors of Charles River Laboratories?
What are Charles River Laboratories' core business segments?
Why is outsourcing to CROs like Charles River Laboratories important?
